Looking Ahead to the Future of CAR T Therapy for B-Cell Lymphoma

Dr Friedman provides closing thoughts emphasizing CAR T's superior long-term data demonstrating curative potential for relapsed/refractory B-cell lymphomas, with promising results extending to other lymphoma types and multiple myeloma. He stresses that community oncologists must prioritize CAR T awareness for eligible patients, as it represents the best available option for cure in the relapsed/refractory setting.

He highlights the gratifying nature of caring for CAR T patients in community settings, emphasizing that oncology requires team-based approaches making investment in staff education and experience development worthwhile. Dr Friedman predicts inevitable expansion of CAR T to community sites driven by various factors, along with future applications including solid tumor bispecifics, CAR T for solid tumors, and autoimmune diseases. This evolution will require oncologists beyond hematology specialists to develop CAR T management competency.

Lynch reflects on her experience from the fearful early days of CAR T to current confidence in algorithmic management approaches. She describes the evolution from sending half of the patients to intensive care unit (ICU) initially to rarely requiring ICU care currently, emphasizing improved toxicity management protocols. Lynch finds satisfaction in witnessing neurologic recovery and complete responses on day-30 scans, describing these moments as among the most rewarding experiences in medicine. Both panelists emphasize CAR T's revolutionary impact on lymphoma care and excitement about future developments in the field.